AN2 Therapeutics

ANTX

The current AN2 Therapeutics (ANTX) market capitalization is approximately $124.00M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, AN2 Therapeutics's market cap fluctuates with changes in its share price and share count. Last updated: April 2, 2026 at 11:09 AM Eastern Time

In the most recently reported quarter, AN2 Therapeutics (ANTX) generated $0.00 in revenue, representing a +0.00% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately $0.00, implying an expected +0.00% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: April 2, 2026 at 6:56 AM Eastern Time

In the most recently reported fiscal year, AN2 Therapeutics (ANTX) generated net income of $-35.17M, compared with $-51.32M in the prior fiscal year, representing a +31.46% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of $-27.70M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: April 2, 2026 at 6:56 AM Eastern Time

Based on the latest available data, AN2 Therapeutics (ANTX) is currently trading at a last twelve months (LTM) P/E ratio of -2.96x. Looking forward, the stock trades at a next twelve months (NTM) P/E ratio of -3.81x, based on consensus earnings estimates. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: April 2, 2026 at 11:45 AM Eastern Time

In the most recently reported quarter, AN2 Therapeutics (ANTX) revenue was $0.00, compared with analyst consensus expectations of $0.00, representing a +0.00% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were $-0.29, compared with consensus estimates of $-0.24, resulting in an -20.83% EPS surprise. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: April 2, 2026 at 6:56 AM Eastern Time

AN2 Therapeutics's (ANTX) earnings reports, including quarterly and annual financial statements, are available through the company's official regulatory filings with the U.S. Securities and Exchange Commission (SEC). On Gainify, you can access AN2 Therapeutics's full set of filings, including earnings releases, Form 10-Q, Form 10-K, and other disclosures, in one place: AN2 Therapeutics SEC Filings These filings provide detailed information on AN2 Therapeutics's financial performance and are considered the primary source of verified financial data for publicly traded companies.

AN2 Therapeutics (ANTX) does not currently pay a dividend. Over the last twelve months (LTM), the company paid $0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: April 2, 2026 at 6:56 AM Eastern Time

Analyst assessments of whether AN2 Therapeutics (ANTX) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: $3.43Consensus price target: $1.00Implied return: -71.01% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: April 2, 2026 at 11:45 AM Eastern Time

Based on the latest available analyst coverage, AN2 Therapeutics (ANTX) currently carries a Hold consensus rating. Analysts' average ANTX price target is $1.00. Relative to the current share price of $3.43, this suggests a potential price change of approximately -71.01%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: April 2, 2026 at 11:45 AM Eastern Time

Like other publicly traded stocks, AN2 Therapeutics (ANTX) shares are bought and sold on stock exchanges such as Nasdaq and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for AN2 Therapeutics (ANTX) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add ANTX to your watchlist.

AN2 Therapeutics trades under the ticker symbol ANTX on the Nasdaq stock exchange. The ticker ANTX is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, AN2 Therapeutics (ANTX) employs approximately 21 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: April 2, 2026 at 11:09 AM Eastern Time

AN2 Therapeutics (ANTX) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest AN2 Therapeutics (ANTX) stock peers based on overlapping products, services, and competitive dynamics:Innoviva (INVA)Theravance Biopharma (TBPH)60 Degrees Pharmaceuticals (SXTP)Reviva Pharmaceuticals Holdings (RVPH)Cumberland Pharmaceuticals (CPIX)Provectus Biopharmaceuticals (PVCT)Guilin Sanjin Pharmaceutical (002275)Hainan Huluwa Pharmaceutical Group (605199) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to AN2 Therapeutics.